Global Interventional Oncology Market Expected to Generate a Value of $1,506.3 Million by 2025

Dublin, Sept. 03, 2019 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market by Procedure [Embolization (TARE, TACE), Ablation (Thermal Ablation (Microwave, RF Ablation))], Product, Application (Liver, Lung, Breast), and End User - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global interventional oncology market is estimated to grow at a CAGR of 7.7% from 2019 to reach $1,506.3 million by 2025.

The global interventional oncology market study presents historical market data in terms of values (2017 and 2018), estimated current data (2019), and forecasts for 2025-by procedure (embolization [TARE, TACE], ablation thermal ablation [microwave, RF ablation]), by product (embolization [SIR-spheres, theraspheres], ablation), application (liver, lung, breast), end-user (hospitals, ambulatory care center), and geography.

The study also evaluates industry competitors and analyzes the market at regional and country level.

Embolization products segment is estimated to command the largest share of the global interventional oncology market in 2019 and expected to witness high growth during the forecast period mainly due to the preference for embolization procedures owing to its benefits such as better clinical outcomes, high specificity & sensitivity towards tumor cells, and efficiency in targeting and detection of tumor lesions. However, the fastest growth in this market is mostly driven by increasing application base of embolization products across various cancer types, rising coverage of reimbursement across the globe, and increasing incidence of cancer & related mortality.

The interventional oncology market for hospitals (end-user segment) is estimated to command the largest share of the global market in 2019. This is attributed to the large volume of patients visiting hospitals for diagnosis & treatment of any healthcare concern including a critical disease like cancer owing to the wide presence, easy accessibility and better healthcare facilities in hospitals.

North America commanded the largest share of the global interventional oncology market, mainly attributed to the factors such as well-established healthcare system including hospitals and ASCs in the North American region, greater adoption of advanced technologies, high level of awareness & spending towards overall healthcare and cancer, growing incidence & prevalence of cancer, presence of key players, and high level of Medicare & Medicaid health insurance coverage.

Key Topics Covered:

1. Introduction
1.1. Market Ecosystem
1.2. Currency and Limitations
1.2.1. Currency
1.2.2. Limitations
1.3. Key Stakeholders

2. Research Methodology
2.1. Secondary Research
2.2. Primary Research

3. Executive Summary

4. Market Insights
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Growing Preference for Minimally invasive Treatment Procedures
4.2.1.2. Increasing Incidence & Prevalence of Cancer
4.2.1.3. Rising Number of Hospitals
4.2.1.4. Technological Advancements in the Field of Radiology
4.2.2. Restraints
4.2.2.1. Potential Risks Associated with Interventional Oncology Procedures
4.2.2.2. High Cost Associated with Interventional Oncology Procedures
4.2.2.3. Paucity of Skilled Healthcare Professionals
4.2.3. Opportunities
4.2.3.1. Significant Growth Opportunities from Emerging Asian and Latin American Markets
4.2.3.2. Introduction of Cloud-Based Medical Imaging
4.2.4. Trend
4.2.4.1. Growing Integration of Image-Guided Solutions with Interventional Oncology Procedures

5. Interventional Oncology Market, by Procedure
5.1. Introduction
5.2. Tumor Embolization
5.2.1. Transarterial Radioembolization (TARE)
5.2.2. Transarterial Chemoembolization (TACE)
5.2.3. Bland Embolization
5.3. Tumor Ablation
5.3.1. Thermal Ablation
5.3.1.1. Radiofrequency Ablation (RFA)
5.3.1.2. Microwave Ablation (MWA)
5.3.1.3. Cryoablation
5.3.1.4. Other Thermal Ablation Procedures
5.3.2. Non-Thermal Ablation

6. Interventional Oncology Market, by Product
6.1. Introduction
6.2. Tumor Embolization
6.2.1. Radioembolic Agents
6.2.1.1. Sir-Spheres
6.2.1.2. TheraSphere
6.2.1.3. QuiremSpheres
6.2.2. Non-Radioactive Embolic Agents
6.2.2.1. Microspheres
6.2.2.2. Particles (PVA Particles and Gelfoam Particles)
6.2.2.3. Drug-Eluting Beads (DEBs)
6.3. Tumor Ablation
6.3.1. Tumor Ablation Devices/Generators
6.3.2. Consumables & Accessories

7. Interventional Oncology Market, by Application
7.1. Introduction
7.2. Liver Cancer
7.3. Lung Cancer
7.4. Breast Cancer
7.5. Prostate Cancer
7.6. Kidney Cancer
7.7. Bone Metastasis
7.8. Other Cancers

8. Interventional Oncology Market, by End User
8.1. Introduction
8.2. Hospitals
8.3. Ambulatory Surgery Centres
8.4. Research and Academia

9. Interventional Oncology Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific
9.5. Rest of World
9.5.1. Latin America
9.5.2. Middle East & Africa

10. Competitive Landscape
10.1. Growth Strategies
10.2. Competitive Benchmarking
10.3. Market Share Analysis (2018)

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments)
11.1. Boston Scientific Corporation
11.2. Cook Medical LLC (A Subsidiary of Cook Group)
11.3. Merit Medical Systems, Inc.
11.4. C. R. Bard, Inc. (A Subsidiary of Becton Dickinson & Company)
11.5. Profound Medical Corp.
11.6. AngioDynamics, Inc.
11.7. BTG plc
11.8. Terumo Corporation
11.9. Medtronic plc
11.10. Healthtronics, Inc.
11.11. EDAP TMS S.A.
11.12. Neuwave Medical, Inc. (Subsidiary of Ethicon Inc.)
11.13. Sirtex Medical Limited
11.14. Trod Medical
11.15. Teleflex Incorporated
11.16. IMBiotechnologies Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/tpi4gy

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900